España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Sickle Cell Disease
Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up
Read Why Imara Shares Are Falling Today
Global Blood Therapeutics' Oxbryta Scores European Approval For Sickle Cell Disease
Read Why Imara Shares Are Falling Today
Global Blood Therapeutics' Oxbryta Scores European Approval For Sickle Cell Disease
Why Are Bluebird Bio Shares Trading Lower Today?
FDA Expands Use Of Global Blood' Sickle Cell Treatment To Kids Aged 4-12 Years
Why Are Bluebird Bio Shares Trading Lower Today?
FDA Expands Use Of Global Blood' Sickle Cell Treatment To Kids Aged 4-12 Years
Global Blood Raises $300M Via Convertible Debt Offering
Bluebird Bio Posts Updated Data From Sickle Cell Gene Therapy Program
Read More...
Sickle Cell Disease Recent News
Fulcrum Therapeutics Shares Additional Data From Phase 1 Trial Of Sickle Cell Disease Treatment
Fulcrum Therapeutics Inc (NASDAQ: FULC) has announced
Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial
Imara Inc (NASDAQ: IMRA) has announced a
See Why Jefferies Sees Massive Upside In Global Blood Therapeutics
Global Blood's Sickle Cell Medicine Under FDA Review For Expanded Use
Vertex Inks Potential $1.2B Gene-Editing Pact With Arbor Biotechnologies
Imara Raises $50M In Equity Funding To Support Development Of Sickle Cell Treatment Candidate
Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease
Forma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease Study
GBT In-Licenses Two Sickle Cell Disease Programs From Sanofi
Global Blood Therapeutics Inc (NASDAQ: GBT) has
Cyclerion Sinks As Biopharma Shelves Sickle Cell Disease Study
Cyclerion Therapeutics Inc (NASDAQ: CYCN) shares are pulling back sharply following a couple of clinical trial updates from the company.
Marijuana Shows Promise In Sickle Cell Disease Treatment
This article was originally published on The Fresh Toast, and appears here with permission.
GlycoMimetics Falls 50% After Disappointing Results For Sickle Cell Drug Trial
Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued
Jefferies Calls Bluebird Bio The 'Star' Of This Year's ASH Meeting
Bluebird Bio's Wings Clipped, Morgan Stanley Downgrades
Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy
Why Have Shares Of Global Blood Therapeutics Skyrocketed Since Its Debut?